We are live on
!
Find out more
JGUA
John G. Ullman & Associates Portfolio holdings
AUM
$754M
1-Year Est. Return
60.05%
This Fund
S&P 500
This Quarter
Est. Return
+1.91%
1 Year Est. Return
+60.05%
3 Year Est. Return
+108.28%
5 Year Est. Return
+118.76%
10 Year Est. Return
+308.24%
AUM
$643M
AUM Growth
+$15.8M
(+2.5%)
Cap. Flow
+$13.3M
Cap. Flow
% of AUM
2.06%
Top 10 Holdings %
Top 10 Hldgs %
33.51%
Holding
182
New
13
Increased
48
Reduced
82
Closed
5
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Equinor
EQNR
|
+$3.96M |
| 2 |
Dominion Energy
D
|
+$2.87M |
| 3 |
American Tower
AMT
|
+$2.78M |
| 4 |
Amazon
AMZN
|
+$2.42M |
| 5 |
Lumentum
LITE
|
+$2.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ExxonMobil
XOM
|
+$12M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
+$3.07M |
| 3 |
SLB Ltd
SLB
|
+$1.14M |
| 4 |
Emerson Electric
EMR
|
+$987K |
| 5 |
AQUA
Evoqua Water Technologies Corp. Common Stock
AQUA
|
+$788K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.64% |
| 2 | Healthcare | 19.97% |
| 3 | Industrials | 16.39% |
| 4 | Utilities | 13.71% |
| 5 | Energy | 6.29% |
Similar funds
HCM
FSCM
RMC
BEC
GFM
TPW
MWA
TCMI
John G. Ullman & Associates's Q1 2023 Portfolio in Review
As of Q1 2023, John G. Ullman & Associates held 182 positions worth $643M, up 2.5% from $627M the previous quarter. Its ten largest holdings account for 34% of the portfolio.
John G. Ullman & Associates's Q1 2023 filing shows 13 new, 48 increased, 82 reduced and 5 closed positions. Its largest new stake was United Therapeutics: 8,425 shares worth $1.89M. The largest sale was ExxonMobil, an estimated $12M.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 24% a quarter earlier, followed by Healthcare and Industrials.
- John G. Ullman & Associates's largest Q1 2023 buy was United Therapeutics: 8,425 shares worth $1.89M.
- John G. Ullman & Associates added most to Equinor in Q1 2023, an estimated $3.96M increase.
- John G. Ullman & Associates's biggest Q1 2023 reduction was ExxonMobil, cutting an estimated $12M.
- John G. Ullman & Associates fully exited Regeneron Pharmaceuticals in Q1 2023, selling an estimated $3.07M.
- John G. Ullman & Associates's ten largest holdings make up 34% of its $643M portfolio in Q1 2023.
- John G. Ullman & Associates opened 13 new positions and closed 5 in Q1 2023.
- John G. Ullman & Associates's portfolio value rose 2.5% quarter-over-quarter to $643M.
Based on John G. Ullman & Associates's 13F filing for Q1 2023, filed 5 May 2023.